A phase II study of ruxolitinib in 53 patients with relapsed/refractory PTCL reported an ORR of 29% among patients with activating JAK/STAT mutations (70). This evidence concerns the gene SOAT1 and mature T-cell and NK-cell non-Hodgkin lymphoma.